Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Best Pathway To Interchangeable Insulins Is In The Eye Of The Beholder

Executive Summary

Approaches suggested at a US FDA public hearing include allowing follow-on insulins to take a direct route to interchangeability without first having to be approved as biosimilars, and automatically declaring biosimilar insulins interchangeable with one or more reference products.

Advertisement

Related Content

Pink Sheet Podcast: Oncology Reviews, Biosimilars, and More Biosimilars
Interchangeable Insulins Could Be Left Out Of Diabetes Treatment ‘Ecosystem’
Biosimilar Interchangeability Switching Studies May Use Foreign Comparators, US FDA Says
US FDA's Gottlieb Shuts The Door On Exclusivity For 'Transition' Biologics
Biosimilars: Postmarketing Data Alone Not Enough For Interchangeability

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS125288

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel